WO2010058280A1 - 自己磁性金属サレン錯体化合物 - Google Patents
自己磁性金属サレン錯体化合物 Download PDFInfo
- Publication number
- WO2010058280A1 WO2010058280A1 PCT/IB2009/007525 IB2009007525W WO2010058280A1 WO 2010058280 A1 WO2010058280 A1 WO 2010058280A1 IB 2009007525 W IB2009007525 W IB 2009007525W WO 2010058280 A1 WO2010058280 A1 WO 2010058280A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- ano
- tumor
- metabolic
- drug
- Prior art date
Links
- 229910052751 metal Inorganic materials 0.000 title claims abstract description 11
- 239000002184 metal Substances 0.000 title claims abstract description 11
- 150000001875 compounds Chemical class 0.000 title claims description 92
- VEUMANXWQDHAJV-UHFFFAOYSA-N 2-[2-[(2-hydroxyphenyl)methylideneamino]ethyliminomethyl]phenol Chemical compound OC1=CC=CC=C1C=NCCN=CC1=CC=CC=C1O VEUMANXWQDHAJV-UHFFFAOYSA-N 0.000 title abstract 3
- 239000003814 drug Substances 0.000 claims abstract description 56
- 229940079593 drug Drugs 0.000 claims abstract description 47
- 239000000696 magnetic material Substances 0.000 claims abstract description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 63
- 230000002503 metabolic effect Effects 0.000 claims description 28
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 17
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- 239000001257 hydrogen Substances 0.000 claims description 14
- 230000001093 anti-cancer Effects 0.000 claims description 12
- 239000002994 raw material Substances 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 8
- 239000003242 anti bacterial agent Substances 0.000 claims description 8
- 229940088710 antibiotic agent Drugs 0.000 claims description 8
- 239000011734 sodium Substances 0.000 claims description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 229910052708 sodium Inorganic materials 0.000 claims description 7
- 239000012620 biological material Substances 0.000 claims description 6
- 238000013329 compounding Methods 0.000 claims description 6
- 229910052697 platinum Inorganic materials 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 230000003115 biocidal effect Effects 0.000 claims description 5
- 229910052742 iron Inorganic materials 0.000 claims description 5
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 4
- 206010000496 acne Diseases 0.000 claims description 4
- 230000008030 elimination Effects 0.000 claims description 3
- 238000003379 elimination reaction Methods 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 229910052727 yttrium Inorganic materials 0.000 claims description 3
- 241000532370 Atla Species 0.000 claims description 2
- 235000008597 Diospyros kaki Nutrition 0.000 claims description 2
- 244000236655 Diospyros kaki Species 0.000 claims description 2
- 241001471005 Melasis Species 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 229940125904 compound 1 Drugs 0.000 claims description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052737 gold Inorganic materials 0.000 claims description 2
- 239000010931 gold Substances 0.000 claims description 2
- 150000002431 hydrogen Chemical group 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 2
- YQMUORJJDBQCOV-UHFFFAOYSA-N $l^{1}-phosphanylmethane Chemical compound [P]C YQMUORJJDBQCOV-UHFFFAOYSA-N 0.000 claims 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 claims 1
- 101150054111 Aspg gene Proteins 0.000 claims 1
- 241000282994 Cervidae Species 0.000 claims 1
- 101001123332 Homo sapiens Proteoglycan 4 Proteins 0.000 claims 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 1
- 102100028965 Proteoglycan 4 Human genes 0.000 claims 1
- 241000276425 Xiphophorus maculatus Species 0.000 claims 1
- 241001599774 Zilla <spider> Species 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 239000002131 composite material Substances 0.000 claims 1
- 229940125797 compound 12 Drugs 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 239000002304 perfume Substances 0.000 claims 1
- 238000010079 rubber tapping Methods 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 238000007796 conventional method Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 28
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 18
- 239000003795 chemical substances by application Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 201000011510 cancer Diseases 0.000 description 11
- 239000004575 stone Substances 0.000 description 11
- 239000002246 antineoplastic agent Substances 0.000 description 10
- 229940041181 antineoplastic drug Drugs 0.000 description 10
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 230000032823 cell division Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 5
- 238000004949 mass spectrometry Methods 0.000 description 5
- 241001026509 Kata Species 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000004445 quantitative analysis Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 229940126214 compound 3 Drugs 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000270322 Lepidosauria Species 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 2
- 241001504505 Troglodytes troglodytes Species 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- RLDQYSHDFVSAPL-UHFFFAOYSA-L calcium;dithiocyanate Chemical compound [Ca+2].[S-]C#N.[S-]C#N RLDQYSHDFVSAPL-UHFFFAOYSA-L 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 208000031513 cyst Diseases 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 208000024963 hair loss Diseases 0.000 description 2
- 230000003676 hair loss Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 230000005415 magnetization Effects 0.000 description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
- 229960004961 mechlorethamine Drugs 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 238000001668 nucleic acid synthesis Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229910052705 radium Inorganic materials 0.000 description 2
- HCWPIIXVSYCSAN-UHFFFAOYSA-N radium atom Chemical compound [Ra] HCWPIIXVSYCSAN-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- JNELGWHKGNBSMD-UHFFFAOYSA-N xanthone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3OC2=C1 JNELGWHKGNBSMD-UHFFFAOYSA-N 0.000 description 2
- PUAQLLVFLMYYJJ-UHFFFAOYSA-N 2-aminopropiophenone Chemical compound CC(N)C(=O)C1=CC=CC=C1 PUAQLLVFLMYYJJ-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- CZRCFAOMWRAFIC-UHFFFAOYSA-N 5-(tetradecyloxy)-2-furoic acid Chemical compound CCCCCCCCCCCCCCOC1=CC=C(C(O)=O)O1 CZRCFAOMWRAFIC-UHFFFAOYSA-N 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 101100456282 Caenorhabditis elegans mcm-4 gene Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000252210 Cyprinidae Species 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241001440206 Homodes Species 0.000 description 1
- OLYPWXRMOFUVGH-LURJTMIESA-N N(2)-methyl-L-lysine Chemical compound CN[C@H](C(O)=O)CCCCN OLYPWXRMOFUVGH-LURJTMIESA-N 0.000 description 1
- 229910052779 Neodymium Inorganic materials 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 241000534944 Thia Species 0.000 description 1
- WWXBHTZSYYGCSG-UHFFFAOYSA-N [4-(carbamoylamino)phenyl]arsonic acid Chemical compound NC(=O)NC1=CC=C([As](O)(O)=O)C=C1 WWXBHTZSYYGCSG-UHFFFAOYSA-N 0.000 description 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
- 229960004176 aclarubicin Drugs 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000009937 cyclo 3 Substances 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000005307 ferromagnetism Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 231100000567 intoxicating Toxicity 0.000 description 1
- 230000002673 intoxicating effect Effects 0.000 description 1
- 229910052741 iridium Inorganic materials 0.000 description 1
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- CBMFIOOVRYZOBT-DAWNIORJSA-N mitomycin k Chemical compound O=C1C(OC)=C(C)C(=O)C2=C1C(=C)[C@]1(OC)N2C[C@H]2[C@@H]1N2C CBMFIOOVRYZOBT-DAWNIORJSA-N 0.000 description 1
- QEFYFXOXNSNQGX-UHFFFAOYSA-N neodymium atom Chemical compound [Nd] QEFYFXOXNSNQGX-UHFFFAOYSA-N 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 101150101156 slc51a gene Proteins 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 235000013547 stew Nutrition 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/295—Iron group metal compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
- C07C251/24—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to carbon atoms of six-membered aromatic rings
Definitions
- the present invention relates to a self-body compound having a self property.
- a drug is administered to a living body and reaches a part, and produces a therapeutic result by producing a result in the local part.
- the drug reaches the outside (mari), it cannot be treated.
- drug which induces drugs to the affected area
- This drag has at least two points. This means that a sufficiently high drug level can be obtained in some tissues. It does not occur unless the drug level in the affected area is constant, and results cannot be expected at low concentrations.
- the agent can be guided only to the affected tissue to suppress the action of normal tissue.
- the drug is most effective for cancer caused by anticancer drugs.
- Most anti-cancer drugs inhibit cancer cell growth that causes cell division, so even normal tissue suppresses growth of cells that cause cell division, such as roots and digestive membranes. To do.
- cancer patients who have been administered anticancer drugs have effects such as hair loss and vomiting. These side effects are a heavy burden on the patient, so the dosage must be limited, and there is a problem that sufficient anticancer drug results cannot be obtained.
- oncological drugs the ability to bind aki () to acne tumors, nucleic acid white, etc. is also a generic term for anti-cancer drugs. Inhibits the production of N, resulting in cells. It works on cells in the working phase regardless of the cell stage, and has a strong effect on proliferating cells, and easily damages bone marrow, digestion, reproduction, hair roots, and the like.
- Biomaterials are substances produced by microorganisms
- results are shown by directly applying to the minute, which plays an important role in maintaining the function of cells, such as the formation of microscopically during cell division and the transport of substances in cell organs. It affects cells and nerve cells where cell division is active.
- Platinum preparations also inhibit N formation by forming N or a bond. Splat is a typical agent, but the damage is strong and abundant.
- molecules are therapeutic methods targeting children that correspond to molecular biological features specific to each sex tumor.
- topomelase an enzyme that temporarily cuts N and changes the number of N chains.
- Topoi melase 1 is an enzyme that cuts the strand of the cyclic N, passes the other strand, then closes the cut, and topo melase 1 temporarily cleaves the two of the cyclic N In the meantime, another 2 N is passed between them, and the cut is again a gap.
- Anti-cancer drugs mostly suppress the growth of cancer cells that cause cell division, so even normal tissues suppress the growth of tissues that cause cell division, such as roots and digestive membranes. I did it. For this reason, cancer patients who have been administered anti-cancer drugs have effects such as hair loss and vomiting.
- anti-cancer drugs can be induced to cancer cells by dragging and concentrating on the cancer cells to exert their effects, thereby suppressing side effects and effectively treating cancer. It has been done. There is a kind of topic, even locally.
- Kai product name Kikaine
- Kai is effective but has arrhythmia.
- drugs can be used to induce anticancer drugs to cancer cells and concentrate on the cancer cells to exert their results, thereby suppressing side effects and effectively cancer. It has been done.
- Drugs are also expected to prevent local dispersal and achieve reduced drug efficacy and side effects.
- the present invention is characterized by the following.
- the charge dynamics are preferably 5 (e).
- R is a local intoxicating agent having a self-body compound in which R is a deviation of any of (28) to (38) in which hydrogen is eliminated from a compound having a methyl group and a charge movement of 0 5 (e). is there.
- R is a compound having any of the following compounds (39) to (03), which is bonded to the case of the compound 1 or 1 by the bond formed by the elimination of hydrogen.
- a (C) is a bond.
- This is a sex tumor agent having an autologous compound.
- G aT is pVa Gy
- R is a sex tumor having an autologous compound comprising the following (04) to (09) compounds.
- one of the 8 positions in the following compound 11 is a self-element that imparts sex to the compound when it is bonded to another compound.
- any one of the 8 positions in the following compound V, and any one of the 96 positions are self-children that bind to other compounds to impart a property to the object.
- a body for producing a magnetic body comprising the following compounds.
- Each R is hydrogen, or one is hydrogen and the other is Ox (x is O or ge).
- 2x of the following compound 11 is a method of a sex form in which a drug molecule is bonded to the position of 5 via an ad group.
- Sex is obtained in the child structure of one sex compound that is chemically combined with the body containing the drug, and by controlling the field when this child structure is administered to an animal, the drug molecule is controlled. It is possible to provide a sex body that exerts fruit by being guided to the target site and localized in the affected area. A simple description of the surface
- Fig. 5 is a plan view showing the main points of a state where stones are brought into contact with a frus with a ground of 6 rats.
- 3 is a graph showing the big of N.
- Fig. 7 is a graph showing the results of N of a compound in which xeno is bound.
- Ming has its own pharmacology (for example), and has the property of combining sex with other drugs to impart sex to drugs.
- the body was made as follows.
- the compound of po yphospho c ac d (200) was 0 C.
- the compound was completely dissolved in 500 liters of water. Furthermore, when the 400 h was added, it was separated into the second phase. 44 As a result of removing the aqueous phase and drying the remaining product with an agent 2 and anhydrous, a COOD 2 of 7 (57) was formed.
- n was z (ES S) 322 4 (eo 7mu) H nN0 eq esm z32 23 was z (ES M 3184 eo 0 m) and H4 N0 eq esm z 318 29.
- I entered from Tokyo Narita (T 0318 CS 4167 8) o
- o sa en In comparison with Fe sa en, o sa en has a lot of magnetization on the field of 100000e (T (Tesla)). n sa en has more magnetization on 300000e (3T (Tesla)) than Fe sa en.
- Fe sa en is suitable for a drug system that uses a large amount of iron even under 00000e (T (Tesla)).
- T (Tesla) the formation of the field o sa en n sa en in a magnetic field above 10 e T (Tesla) is the most suitable for a drug stem that uses conductive stone.
- Fig. 5 shows the contact of a rat with 6 rat follicles.
- Fig. 6 shows the result of calculating the number of cells after photographing from the end of the lath surface after 48 hours.
- the magnets indicate the area opposite to the lath surface. As shown in Fig. 6, it can be seen that n bodies are attracted from the magnet, and the body is increased, and the cells are extremely low than far away for the production of the body. As a result, the stem provided with the magnetic agent and the magnetic generation stage according to the present invention can concentrate the agent on the affected area or tissue targeted by the individual.
- a guidance device In this guide device, as shown in FIG. 7, a pair of 230s facing each other are supported by a stud 234 club 235, and a metal 236 is placed between magnets.
- a metal especially a steel plate, as a pair, a uniform and strong field can be created locally.
- This induction device can change the generated force by using electromagnets instead of stones.
- the force generation stage can be moved to the target position of the solid on the table. By placing a solid weave in this area, the drug can be concentrated in this weave. Place the mouse on the board so that the right kidney is between the pair of stones.
- Figure 9 shows the results of the body against the length in us. No was formed to n V vo in Us by the planting of No (Kun 3 No).
- the body was applied from the tail vein (50 g kg), and a local field was prepared using commercially available (63 T, cylindrical iridium, length 50, diameter 2 O). Immediately after putting the stone body into 0-4, it was done by bringing the nocite into contact with 3 or.
- the stone was run for a long period of time between 2 and 0 below the mouse so that the maximum magnetic field was expected at the site where the length was expected. After the insertion of the body, the length of the cell was evaluated by evaluating the region of the cell.
- the degree of 10C was increased from 2C (2). This is
- N 3 indicates N big
- 4 indicates N big
- 5 indicates big
- 6 indicates big. Because n,, and are sex bodies, the spin number detected by N is symbiotic with the electron spin number that appears for magnetic bodies.
- the magnetic material is 3 ⁇ 442 p, 3 ⁇ 03 gpp, 2 ⁇ 4 5 pp, 2 ⁇ 6 pp, 3 ⁇ 14 gppn, Fe is 2 ⁇ 52 2 pp and 3 ⁇ 347 pm, and 2 pp is confirmed. On the other hand, if it is not a magnetic material, there is no peak at 2pp.
- compound 3 e (di) d ca bona e) was liquefied and allowed to stand overnight. After reacting by vaporizing in the air, the adhered oil was dropped with methano and Na H solution was added. Washed away. Then, compound 5 was obtained by making a raw clay using a lizard as a raw material.
- Fig. 7 shows N results.
- Fig. 8 shows the results of mass spectrometry.
- the compound 5 was poured into a chea (EH) stream while heating, and a thiazia solution was added. The mixture was again flushed 0.5. And when the collected items were collected with a filter, yellow As a result, 6 was obtained.
- implementation 8 is the same.
- Rat 6 In the medium, inoculate the medium with a chemical () and (eb oz) compound that can be attracted to woodwork 4 ⁇ 7 (T) conduction (Kugnet). After 48 hours, I photographed the state of the earth.
- the system comprising the magnetic agent and the magnetic generation stage according to the present invention makes it possible to concentrate the drug on the affected area or tissue targeted by the individual.
- the amount of the compound bound to (e b oz) was sprinkled on the medium so that it could be attracted to wood craft 4/7 () conduction (Kutto net), and the state of the ground was photographed after 48 hours.
- the system that realizes this function is provided with a doer source as a pin, that is, a memo, a computing device having a path such as a PU, and a display stage for outputting a computation result.
- Memo is equipped with a software program that realizes data and data that identifies existing mechanical compounds or structures.
- the region of the spin degree described is calculated, and the spin degree as a structure is effective.
- this program for example, commercially available (, access) can be used. 60
- the user enters the position to add to the compound, selects or changes or deletes, and uses the other program to determine where the bridge is formed. specify.
- the arithmetic unit calculates the speed and outputs the result to the display surface.
- the arithmetic unit calculates the speed and outputs the result to the display surface.
- the flower composition to be combined 033 Add 33 Cyclo 3 32 32 33 and 33033 Huaran. 33 28 Mustine 028 Phosphorus Ramustinium 030 ⁇ 3f Mustine 31 ⁇ 39 Xel 39 ⁇ ccNristine 038 3 Nblastine 0 ⁇ 38 ⁇ 23 Sin 2 33 Levin 33 ⁇ 29 Pin Sin 29 5 Saliplatin 025 2 Carpoplatin 22
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09827243.8A EP2357166B1 (en) | 2008-11-20 | 2009-11-20 | Auto magnetic metal salen complex compound |
CN2009801465709A CN102239138A (zh) | 2008-11-20 | 2009-11-20 | 自磁性金属salen络合物 |
RU2011124913/04A RU2495045C2 (ru) | 2008-11-20 | 2009-11-20 | Комплексное соединение самонамагничивающегося металла с саленом |
JP2010539038A JP5513405B2 (ja) | 2008-11-20 | 2009-11-20 | 自己磁性金属サレン錯体化合物 |
US13/112,409 US9505732B2 (en) | 2008-11-20 | 2011-05-20 | Auto magnetic metal salen complex compound |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008-297065 | 2008-11-20 | ||
JP2008297065 | 2008-11-20 | ||
JP2008299482 | 2008-11-25 | ||
JP2008-299482 | 2008-11-25 | ||
JP2009-177112 | 2009-07-29 | ||
JP2009177112 | 2009-07-29 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/112,409 Continuation US9505732B2 (en) | 2008-11-20 | 2011-05-20 | Auto magnetic metal salen complex compound |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010058280A1 true WO2010058280A1 (ja) | 2010-05-27 |
Family
ID=42197873
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2009/007525 WO2010058280A1 (ja) | 2008-11-20 | 2009-11-20 | 自己磁性金属サレン錯体化合物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US9505732B2 (ja) |
EP (1) | EP2357166B1 (ja) |
JP (1) | JP5513405B2 (ja) |
CN (2) | CN104800195A (ja) |
RU (1) | RU2495045C2 (ja) |
WO (1) | WO2010058280A1 (ja) |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011135784A1 (ja) | 2010-04-28 | 2011-11-03 | 株式会社Ihi | 抗脳腫瘍薬剤 |
WO2012086683A1 (ja) | 2010-12-21 | 2012-06-28 | 株式会社Ihi | 金属サレン錯体化合物及びその製造方法 |
WO2012111380A1 (ja) * | 2011-02-15 | 2012-08-23 | 株式会社Ihi | 自己磁性金属サレン錯体化合物 |
JP2012176905A (ja) * | 2011-02-25 | 2012-09-13 | Ihi Corp | 金属サレン錯体化合物 |
WO2012172892A1 (ja) * | 2011-06-13 | 2012-12-20 | 株式会社Ihi | 金属サレン錯体化合物、局所麻酔薬剤及び抗悪性腫瘍薬剤 |
WO2013008510A1 (ja) | 2011-07-11 | 2013-01-17 | 株式会社Ihi | 電気二重層キャパシタ用材料 |
WO2013014997A1 (ja) | 2011-07-26 | 2013-01-31 | 株式会社Ihi | 自己磁性金属サレン錯体化合物 |
CN102918118A (zh) * | 2010-06-01 | 2013-02-06 | 株式会社Ihi | 荧光色素材料及其使用方法 |
WO2013051389A1 (ja) | 2011-10-04 | 2013-04-11 | 株式会社Ihi | 金属サレン錯体化合物応答性薬剤及び金属サレン錯体化合物の体内挙動制御システム |
WO2013051363A1 (ja) * | 2011-10-06 | 2013-04-11 | 株式会社Ihi | 磁性組成物及びその製造方法 |
WO2013061724A1 (ja) | 2011-10-27 | 2013-05-02 | 株式会社Ihi | ラジカル抑制剤 |
US20140039126A1 (en) * | 2011-02-05 | 2014-02-06 | Bridgestone Corporation | Lanthanide Complex Catalyst And Polymerization Method Employing Same |
JP2014058493A (ja) * | 2012-09-18 | 2014-04-03 | Hiroshi Kashihara | 強磁性を有する核酸の合成方法と利用方法 |
WO2014092188A1 (ja) | 2012-12-14 | 2014-06-19 | 株式会社Ihi | 磁性体、及び、磁性体の製造方法 |
WO2014123115A1 (ja) | 2013-02-05 | 2014-08-14 | 株式会社Ihi | 磁性体 |
JP2014210742A (ja) * | 2013-04-19 | 2014-11-13 | 株式会社Ihi | 持続性磁性抗がん剤 |
CN104559944A (zh) * | 2014-12-24 | 2015-04-29 | 西安交通大学 | 一种含稀土氢氧化物的磁制冷材料及制备方法 |
JP2015143197A (ja) * | 2014-01-31 | 2015-08-06 | 株式会社Ihi | 新規な金属サレン錯体化合物 |
WO2016046989A1 (ja) * | 2014-09-26 | 2016-03-31 | 株式会社Ihi | 抗がん剤、がん細胞殺傷方法 |
JP2017128553A (ja) * | 2016-01-22 | 2017-07-27 | 株式会社Ihi | 抗癌剤、抗癌剤の制御方法 |
JP2017128552A (ja) * | 2016-01-22 | 2017-07-27 | 株式会社Ihi | 抗癌剤、抗癌剤の制御方法 |
WO2018003587A1 (ja) * | 2016-06-27 | 2018-01-04 | 株式会社クラレ | 鉄錯体の製造方法及び鉄錯体を用いたエステル化合物の製造方法 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090169484A1 (en) * | 2007-12-28 | 2009-07-02 | Ihi Corporation | Iron-salen complex |
EP3124114A4 (en) * | 2014-03-28 | 2017-11-29 | Kyushu University, National University Corporation | Transesterification reaction by means of iron catalyst |
CN107417708B (zh) * | 2017-08-04 | 2019-04-09 | 广西师范大学 | 一种水溶性铜(ii)配合物及其合成方法和应用 |
CN109954516B (zh) * | 2017-12-14 | 2021-12-21 | 中国科学院大连化学物理研究所 | 一种用于手性反式第一菊酸制备的Salen/Ru催化剂 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0545932A (ja) * | 1991-08-12 | 1993-02-26 | Nippon Kayaku Co Ltd | 電子写真用トナー |
JPH10310796A (ja) * | 1997-05-14 | 1998-11-24 | Lion Corp | カビ取り剤組成物 |
JP2001010978A (ja) | 1993-01-29 | 2001-01-16 | Ferx Inc | 生物活性物質を運搬するための磁気応答組成物 |
WO2008001851A1 (en) | 2006-06-28 | 2008-01-03 | Ihi Corporation | Drug, drug induction device, magnetic detector and method of designing drug |
JP2008115129A (ja) * | 2006-11-07 | 2008-05-22 | Ihi Corp | 薬、薬の誘導装置、体内動態検知器及び薬の設計方法 |
JP2008117969A (ja) * | 2006-11-06 | 2008-05-22 | Ihi Corp | 磁性材料、磁性材料の誘導装置及び磁性材料の設計方法 |
JP2009173631A (ja) * | 2007-12-28 | 2009-08-06 | Ihi Corp | 鉄サレン錯体 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1432563A (en) | 1972-04-10 | 1976-04-22 | Rustenburg Platinum Mines Ltd | Platinum- co-ordination compounds |
NL7304882A (ja) | 1972-04-10 | 1973-10-12 | ||
US4727068A (en) | 1985-10-23 | 1988-02-23 | Johnson Matthey, Inc. | Radiosensitization by cobalt and Fe(III) complexes |
US4871716A (en) | 1986-02-04 | 1989-10-03 | University Of Florida | Magnetically responsive, hydrophilic microspheres for incorporation of therapeutic substances and methods of preparation thereof |
JPS62192383A (ja) | 1986-02-20 | 1987-08-22 | Hidetoshi Tsuchida | ポリテトラアザポルフイン鉄錯体および有機磁性材料 |
DE3618840A1 (de) * | 1986-06-04 | 1987-12-10 | Basf Ag | Methanol/luft-brennstoffzellen |
JP3000369B2 (ja) | 1989-05-16 | 2000-01-17 | 日本酸素株式会社 | 酸素吸収錯体の再生方法及び酸素吸収錯体溶液を用いた酸素の分離方法 |
JPH0523276A (ja) | 1991-07-15 | 1993-02-02 | Tokyo Electric Co Ltd | 電気掃除機 |
JPH05216967A (ja) | 1992-02-03 | 1993-08-27 | Hitachi Ltd | 分子設計支援装置 |
US5696109A (en) * | 1992-12-07 | 1997-12-09 | Eukarion, Inc. | Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease |
US5403834A (en) * | 1992-12-07 | 1995-04-04 | Eukarion, Inc. | Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease |
DE4301871A1 (de) | 1993-01-13 | 1994-07-14 | Diagnostikforschung Inst | Neue Mittel zur Diagnose von Gefäßerkrankungen |
US6200547B1 (en) | 1994-01-26 | 2001-03-13 | Ferx Incorporated | Magnetically responsive compositions for carrying biologically active substances and methods of production and use |
JPH07296045A (ja) | 1994-04-27 | 1995-11-10 | Hitachi Ltd | 分子設計支援方法 |
KR100252743B1 (ko) | 1994-12-29 | 2000-09-01 | 나가야마 오사무 | Il-6 안타고니스트를 함유하는 항종양제의 작용증강제 |
JP3724051B2 (ja) * | 1996-04-25 | 2005-12-07 | 住友化学株式会社 | フェノールの酸化重合用触媒およびフェノールの酸化重合法 |
JP3662347B2 (ja) | 1996-06-10 | 2005-06-22 | 日鉄鉱業株式会社 | 医療用粉体 |
JP3825501B2 (ja) | 1996-06-10 | 2006-09-27 | 吉郎 岡見 | 微小物質保持担体、その懸濁系、微小物質操作装置及び微小物質位置制御方法 |
PT1007533E (pt) * | 1996-08-27 | 2005-09-30 | Univ Utah Res Found | Bioconjugados e administracao de agentes bioactivos |
JP3030849B2 (ja) | 1997-06-18 | 2000-04-10 | 科学技術振興事業団 | 有機高分子化合物の強磁性を予測する方法 |
JPH11217385A (ja) | 1998-01-30 | 1999-08-10 | Nihon Schering Kk | 含フッ素ポルフィリン錯体およびそれを含有する造影剤 |
JPH11279100A (ja) * | 1998-03-25 | 1999-10-12 | Asahi Glass Co Ltd | 光学活性な1−置換−2−プロパノールの製造方法 |
US6087368A (en) | 1998-06-08 | 2000-07-11 | Bristol-Myers Squibb Company | Quinazolinone inhibitors of cGMP phosphodiesterase |
JP2000269013A (ja) | 1999-03-12 | 2000-09-29 | Kanagawa Acad Of Sci & Technol | 分子性磁性体 |
DE60031761T2 (de) * | 1999-06-29 | 2007-09-20 | National Institute Of Advanced Industrial Science And Technology | Verfahren zur herstellung einer harzzusammensetzung |
TWI224966B (en) | 1999-11-02 | 2004-12-11 | Pfizer | Pharmaceutical composition (I) useful for treating or preventing pulmonary hypertension in a patient |
JP4433118B2 (ja) | 2000-09-12 | 2010-03-17 | 日産化学工業株式会社 | 分子磁性体およびその製造方法 |
US6589948B1 (en) | 2000-11-28 | 2003-07-08 | Eukarion, Inc. | Cyclic salen-metal compounds: reactive oxygen species scavengers useful as antioxidants in the treatment and prevention of diseases |
GB0125357D0 (en) * | 2001-10-22 | 2001-12-12 | Univ Brighton | Improvements relating to catalytic antioxidants |
WO2003086563A2 (en) | 2002-04-11 | 2003-10-23 | Carbomer, Inc. | Diabetes imaging probes |
JP4357847B2 (ja) | 2003-02-04 | 2009-11-04 | 三菱電機株式会社 | 物質の磁気特性を予測する方法 |
GB0316912D0 (en) | 2003-07-18 | 2003-08-20 | Oxford Instr Superconductivity | Therapeutic treatment |
JP2005154402A (ja) * | 2003-10-29 | 2005-06-16 | Nagoya Industrial Science Research Inst | 金属錯体タンパク質複合体及び酸化触媒 |
US7119065B2 (en) * | 2003-10-29 | 2006-10-10 | Nagoya Industrial Science Research Institute | Metal complex-protein composite and oxidation catalyst |
WO2006133354A2 (en) * | 2005-06-08 | 2006-12-14 | University Of Kansas | Methods for producing nanoparticulate metal complexes and altering nanoparticle morphology |
JP2007091710A (ja) | 2005-08-31 | 2007-04-12 | Ishikawajima Harima Heavy Ind Co Ltd | 薬、薬の誘導装置、磁気検出装置及び薬の設計方法 |
-
2009
- 2009-11-20 WO PCT/IB2009/007525 patent/WO2010058280A1/ja active Application Filing
- 2009-11-20 CN CN201510117014.6A patent/CN104800195A/zh active Pending
- 2009-11-20 EP EP09827243.8A patent/EP2357166B1/en active Active
- 2009-11-20 RU RU2011124913/04A patent/RU2495045C2/ru active
- 2009-11-20 JP JP2010539038A patent/JP5513405B2/ja active Active
- 2009-11-20 CN CN2009801465709A patent/CN102239138A/zh active Pending
-
2011
- 2011-05-20 US US13/112,409 patent/US9505732B2/en active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0545932A (ja) * | 1991-08-12 | 1993-02-26 | Nippon Kayaku Co Ltd | 電子写真用トナー |
JP2001010978A (ja) | 1993-01-29 | 2001-01-16 | Ferx Inc | 生物活性物質を運搬するための磁気応答組成物 |
JPH10310796A (ja) * | 1997-05-14 | 1998-11-24 | Lion Corp | カビ取り剤組成物 |
WO2008001851A1 (en) | 2006-06-28 | 2008-01-03 | Ihi Corporation | Drug, drug induction device, magnetic detector and method of designing drug |
JP2008117969A (ja) * | 2006-11-06 | 2008-05-22 | Ihi Corp | 磁性材料、磁性材料の誘導装置及び磁性材料の設計方法 |
JP2008115129A (ja) * | 2006-11-07 | 2008-05-22 | Ihi Corp | 薬、薬の誘導装置、体内動態検知器及び薬の設計方法 |
JP2009173631A (ja) * | 2007-12-28 | 2009-08-06 | Ihi Corp | 鉄サレン錯体 |
Non-Patent Citations (1)
Title |
---|
SOMU S. ET AL.: "Reactions of Fluorenylidene Nitrile Ylides with (Salen)metal Complexes", INORG. CHEM., vol. 29, no. 17, 1990, pages 3154 - 3157, XP008149338 * |
Cited By (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2564852A1 (en) * | 2010-04-28 | 2013-03-06 | IHI Corporation | Anti-brain-tumor drug |
JP5680065B2 (ja) * | 2010-04-28 | 2015-03-04 | 株式会社Ihi | 抗脳腫瘍薬剤 |
US8933118B2 (en) | 2010-04-28 | 2015-01-13 | Ihi Corporation | Anti-brain-tumor drug |
WO2011135784A1 (ja) | 2010-04-28 | 2011-11-03 | 株式会社Ihi | 抗脳腫瘍薬剤 |
EP2564852A4 (en) * | 2010-04-28 | 2013-10-02 | Ihi Corp | MEDICAMENT TREATING CEREBRAL TUMORS |
US9282923B2 (en) | 2010-06-01 | 2016-03-15 | Ihi Corporation | Fluorochrome material and method for using the same |
RU2540311C2 (ru) * | 2010-06-01 | 2015-02-10 | АйЭйчАй КОРПОРЕЙШН | Флуорохромный материал и способ его применения |
EP2578643A4 (en) * | 2010-06-01 | 2014-01-22 | Ihi Corp | FLUORESCENT COLORING MATERIAL AND USE THEREOF |
EP2578643A1 (en) * | 2010-06-01 | 2013-04-10 | IHI Corporation | Fluorescent dye material and use thereof |
CN102918118A (zh) * | 2010-06-01 | 2013-02-06 | 株式会社Ihi | 荧光色素材料及其使用方法 |
EP2657223A4 (en) * | 2010-12-21 | 2014-12-24 | Ihi Corp | METAL-SALEN COMPLEX COMPOUND AND PROCESS FOR PRODUCING THE SAME |
US9005757B2 (en) | 2010-12-21 | 2015-04-14 | Ihi Corporation | Metal-salen complex compound and method for producing the same |
EP2944627A1 (en) | 2010-12-21 | 2015-11-18 | IHI Corporation | Nanometersized metal salen complex compounds, their preparation and their use as systemic antitumor agents |
RU2546663C2 (ru) * | 2010-12-21 | 2015-04-10 | АйЭйчАй КОРПОРЕЙШН | Комплексное соединение металл-сален и способ его получения |
EP2657223A1 (en) * | 2010-12-21 | 2013-10-30 | IHI Corporation | Metal-salen complex compound and production method for same |
WO2012086683A1 (ja) | 2010-12-21 | 2012-06-28 | 株式会社Ihi | 金属サレン錯体化合物及びその製造方法 |
US20140039126A1 (en) * | 2011-02-05 | 2014-02-06 | Bridgestone Corporation | Lanthanide Complex Catalyst And Polymerization Method Employing Same |
US9469658B2 (en) * | 2011-02-05 | 2016-10-18 | Bridgestone Corporation | Lanthanide complex catalyst and polymerization method employing same |
JP2012167067A (ja) * | 2011-02-15 | 2012-09-06 | Ihi Corp | 自己磁性金属サレン錯体化合物 |
WO2012111380A1 (ja) * | 2011-02-15 | 2012-08-23 | 株式会社Ihi | 自己磁性金属サレン錯体化合物 |
CN103547564A (zh) * | 2011-02-15 | 2014-01-29 | 株式会社Ihi | 自磁性金属salen络合物化合物 |
US20140046021A1 (en) * | 2011-02-15 | 2014-02-13 | Ihi Corporation | Self-magnetic metal-salen complex compound |
JP2012176905A (ja) * | 2011-02-25 | 2012-09-13 | Ihi Corp | 金属サレン錯体化合物 |
JP2013001646A (ja) * | 2011-06-13 | 2013-01-07 | Ihi Corp | 金属サレン錯体化合物、局所麻酔薬剤及び抗悪性腫瘍薬剤 |
US10034851B2 (en) | 2011-06-13 | 2018-07-31 | Ihi Corporation | Metal-salen complex compound, local anesthetic and antineoplastic drug |
CN103781760A (zh) * | 2011-06-13 | 2014-05-07 | 株式会社Ihi | 金属salen络合物化合物、局部麻醉药剂及抗恶性肿瘤药剂 |
CN103781760B (zh) * | 2011-06-13 | 2016-03-30 | 株式会社Ihi | 金属salen络合物化合物、局部麻醉药剂及抗恶性肿瘤药剂 |
EP2738158A4 (en) * | 2011-06-13 | 2014-12-17 | Ihi Corp | METAL-SALEN COMPLEX CONNECTION, LOCAL ANESTHETICS AND MEDIUM AGAINST MALIGNANT TUMORS |
WO2012172892A1 (ja) * | 2011-06-13 | 2012-12-20 | 株式会社Ihi | 金属サレン錯体化合物、局所麻酔薬剤及び抗悪性腫瘍薬剤 |
CN103890886A (zh) * | 2011-07-11 | 2014-06-25 | 株式会社Ihi | 双电层电容器用材料 |
EP2733713A4 (en) * | 2011-07-11 | 2015-05-06 | Ihi Corp | MATERIAL FOR ELECTRICAL CAPACITOR WITH DOUBLE LAYER |
WO2013008510A1 (ja) | 2011-07-11 | 2013-01-17 | 株式会社Ihi | 電気二重層キャパシタ用材料 |
US9208952B2 (en) | 2011-07-11 | 2015-12-08 | Ihi Corporation | Electric double layer capacitor material |
US9592219B2 (en) | 2011-07-26 | 2017-03-14 | Ihi Corporation | Self-magnetic metal-salen complex compound |
WO2013014997A1 (ja) | 2011-07-26 | 2013-01-31 | 株式会社Ihi | 自己磁性金属サレン錯体化合物 |
EP2738157A4 (en) * | 2011-07-26 | 2015-10-14 | Ihi Corp | AUTOMAGNETIC METAL-SALEN COMPLEX CONNECTION |
CN104010660A (zh) * | 2011-10-04 | 2014-08-27 | 株式会社Ihi | 金属Salen配位化合物响应性药剂以及金属Salen配位化合物的体内行为控制系统 |
JPWO2013051389A1 (ja) * | 2011-10-04 | 2015-03-30 | 株式会社Ihi | 金属サレン錯体化合物応答性薬剤及び金属サレン錯体化合物の体内挙動制御システム |
US9468621B2 (en) | 2011-10-04 | 2016-10-18 | Ihi Corporation | Metal-salen complex compound responsive drug and intra-corporeal behavior control system for metal-salen complex compound |
US20140235684A1 (en) * | 2011-10-04 | 2014-08-21 | Yoshihiro Ishikawa | Metal-salen complex compound responsive drug and intra-corporeal behavior control system for metal-salen complex compound |
WO2013051389A1 (ja) | 2011-10-04 | 2013-04-11 | 株式会社Ihi | 金属サレン錯体化合物応答性薬剤及び金属サレン錯体化合物の体内挙動制御システム |
JPWO2013051363A1 (ja) * | 2011-10-06 | 2015-03-30 | 株式会社Ihi | 液剤 |
US20150028250A1 (en) * | 2011-10-06 | 2015-01-29 | Ihi Corporation | Magnetic composition and its production method |
CN104010638A (zh) * | 2011-10-06 | 2014-08-27 | 株式会社Ihi | 磁性组合物及其制造方法 |
WO2013051363A1 (ja) * | 2011-10-06 | 2013-04-11 | 株式会社Ihi | 磁性組成物及びその製造方法 |
WO2013061724A1 (ja) | 2011-10-27 | 2013-05-02 | 株式会社Ihi | ラジカル抑制剤 |
JP2014058493A (ja) * | 2012-09-18 | 2014-04-03 | Hiroshi Kashihara | 強磁性を有する核酸の合成方法と利用方法 |
WO2014092188A1 (ja) | 2012-12-14 | 2014-06-19 | 株式会社Ihi | 磁性体、及び、磁性体の製造方法 |
US9469668B2 (en) | 2013-02-05 | 2016-10-18 | Ihi Corporation | Magnetic substance |
JP2014152121A (ja) * | 2013-02-05 | 2014-08-25 | Ihi Corp | 磁性体 |
WO2014123115A1 (ja) | 2013-02-05 | 2014-08-14 | 株式会社Ihi | 磁性体 |
JP2014210742A (ja) * | 2013-04-19 | 2014-11-13 | 株式会社Ihi | 持続性磁性抗がん剤 |
JP2015143197A (ja) * | 2014-01-31 | 2015-08-06 | 株式会社Ihi | 新規な金属サレン錯体化合物 |
US10030039B2 (en) | 2014-09-26 | 2018-07-24 | Ihi Corporation | Anti-cancer agent and cancer cell killing method |
WO2016046989A1 (ja) * | 2014-09-26 | 2016-03-31 | 株式会社Ihi | 抗がん剤、がん細胞殺傷方法 |
JPWO2016046989A1 (ja) * | 2014-09-26 | 2017-06-22 | 株式会社Ihi | 抗がん剤、がん細胞殺傷方法 |
CN104559944A (zh) * | 2014-12-24 | 2015-04-29 | 西安交通大学 | 一种含稀土氢氧化物的磁制冷材料及制备方法 |
JP2017128552A (ja) * | 2016-01-22 | 2017-07-27 | 株式会社Ihi | 抗癌剤、抗癌剤の制御方法 |
JP2017128553A (ja) * | 2016-01-22 | 2017-07-27 | 株式会社Ihi | 抗癌剤、抗癌剤の制御方法 |
WO2018003587A1 (ja) * | 2016-06-27 | 2018-01-04 | 株式会社クラレ | 鉄錯体の製造方法及び鉄錯体を用いたエステル化合物の製造方法 |
KR20190022533A (ko) * | 2016-06-27 | 2019-03-06 | 주식회사 쿠라레 | 철 착물의 제조 방법 및 철 착물을 사용한 에스테르 화합물의 제조 방법 |
JPWO2018003587A1 (ja) * | 2016-06-27 | 2019-07-11 | 株式会社クラレ | 鉄錯体の製造方法及び鉄錯体を用いたエステル化合物の製造方法 |
US10646859B2 (en) | 2016-06-27 | 2020-05-12 | Kuraray Co., Ltd. | Method for producing iron complexes and method for producing ester compounds using iron complex |
KR102366890B1 (ko) | 2016-06-27 | 2022-02-23 | 주식회사 쿠라레 | 철 착물의 제조 방법 및 철 착물을 사용한 에스테르 화합물의 제조 방법 |
Also Published As
Publication number | Publication date |
---|---|
US20120029167A1 (en) | 2012-02-02 |
EP2357166B1 (en) | 2020-01-15 |
RU2011124913A (ru) | 2012-12-27 |
CN102239138A (zh) | 2011-11-09 |
EP2357166A4 (en) | 2012-07-04 |
CN104800195A (zh) | 2015-07-29 |
JP5513405B2 (ja) | 2014-06-04 |
JPWO2010058280A1 (ja) | 2012-04-12 |
EP2357166A1 (en) | 2011-08-17 |
RU2495045C2 (ru) | 2013-10-10 |
US9505732B2 (en) | 2016-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010058280A1 (ja) | 自己磁性金属サレン錯体化合物 | |
Link et al. | Role of iron in the potentiation of anthracycline cardiotoxicity: identification of heart cell mitochondria as a major site of iron-anthracycline interaction | |
Storr et al. | Design of targeting ligands in medicinal inorganic chemistry | |
Peng et al. | Upconversion nanoparticles dramatically promote plant growth without toxicity | |
AU638127B2 (en) | A bifunctional dtpa-type ligand | |
JP2018162317A5 (ja) | ||
JPH05501264A (ja) | 充実性腫瘍治療法及び組成物 | |
JPH03502936A (ja) | 巨環アミノホスホン酸錯体,その製造,製剤化及び使用 | |
CN100560137C (zh) | 一种载带伯胺基药物的细菌纳米磁小体及其制备方法 | |
EP2072061A1 (en) | Composition and method for generating a metabolic profile using 13C-MR detection | |
CN110403916B (zh) | 一种纳米治疗剂及其制备方法与应用 | |
WO2007108618A1 (en) | Water-soluble organometallic nanoparticles and method for preparing the same | |
AU650944B2 (en) | Method of treating and/or diagnosing soft tissue tumors | |
CN114010598A (zh) | 基于切伦科夫效应的酸响应纳米胶束及其制备方法和应用 | |
CN109517794A (zh) | Gd:Fe3O4@RA纳米粒子诱导神经干细胞定向分化为神经元细胞的方法 | |
JP2001515874A (ja) | モノヒドロキサム酸塩のバナジウム錯体及び当該錯体で構成される医薬品組成物 | |
CN112979686A (zh) | 一种新型硼携带剂、制备方法及其药物制剂 | |
Blanuša et al. | Chelation of aluminium by combining DFO and L1 in rats | |
Alsharedeh et al. | Magnetosomes as Potential Nanocarriers for Cancer Treatment | |
Manning et al. | Iron chelators in medicinal applications-chemical equilibrium considerations in pharmaceutical activity | |
CN110279858B (zh) | 一种具备细胞核靶向性的含硼制剂及其制备方法和应用 | |
JPS5946229A (ja) | 骨格造影に使用する凍結乾燥製品の製造法 | |
Guo et al. | Efficient conjugation doxorubicin to bacterial magnetic nanoparticles via a triplex hands coupling reagent | |
Vanin | Dinitrosyl Iron Complexes with Natural Thiol‐Containing Ligands: Physicochemistry, Biology, and Medicine | |
CN102973513B (zh) | 智能纳米药物传递系统和制备方法及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980146570.9 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09827243 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2010539038 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009827243 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2497/KOLNP/2011 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011124913 Country of ref document: RU |